LEUKEMIA With the patronage of:

Transcription

1 3 nd International Conference LEUKEMIA 2014 Santa Margherita Ligure (Italy) May, 21-24, 2014 With the patronage of: Società Italiana di Ematologia - SIE Società Italiana di Ematologia Sperimentale - SIES Gruppo Italiano Trapianto Midollo Osseo - GITMO Associazione Malattie del Sangue - AMS Associazione Ricerche Emato-Oncologiche - AREO

2 [ Presentation ] The Conference, with the participation of the most important international and Italian experts, wants to provide an update on the most innovative aspects of cell biology, molecular biology and treatment of acute and chronic leukemias, myelodysplastic syndromes and chronic myelodysplasia. One section will be dedicated to the new drugs in onco-hematology. [ Preliminary Program ] Wednesday, May 21 NEW DRUGS IN ONCO-HEMATOLOGY (not for CME credits) Chairmen: Massimo Federico, Pier Luigi Zinzani tbd James Carmichael Novelties in strategic approach to chronical hematological malignancies Alf Bernhardt tbd Andreas Engert tbd Giovanni Martinelli tbd Giuseppe Rossi tbd Daniele Alberti The use of an adaptive trial design in a phase III trial of vosaroxin and cytarabine in relapsed and refractory AML Adam Craig CHALLENGES IN PHILADELPHIA-POSITIVE LEUKEMIAS Chairmen: John M. Goldman, Angelo M. Carella Introduction John M. Goldman Current clinical options in Ph+ ALL Robin Foà Early and deep molecular response predictive of long term outcome in Ph+ leukemias Giovanni Martinelli Ponatinib : bridge to transplant and post transplant clinical strategies Fabio Ciceri Conclusions Angelo M. Carella Round Table BONE MARROW TRANSPLANTATION IN LEUKEMIAS: NEW PERSPECTIVES Chairmen: Andrea Bacigalupo, Alberto Bosi Immunologic pressure after transplant and HLA Fabio Ciceri Unrelated donor transplant for leukemia 2014 Jane F. Apperley

3 Finding a donor for most eligible patients William Arcese HDCT in MDS: indications, timing and optimization of the results. What's new? Emanuele Angelucci End of session Thursday, May Opening Ceremony ACUTE MYELOID LEUKEMIAS IN 2014: SOME UNRESOLVED ISSUES Chairmen: Jacob M. Rowe, Sergio Amadori 8.15 Introduction Jacob M. Rowe 8.20 The increasing role of mutations and genomics in AML Brunangelo Falini 8.40 The increasing clinical relevance of minimal residual disease Gert J. Ossenkoppele 9.00 Is the role of adjunctive therapy to standard 3+7? Alan K. Burnett 9.20 Optimal non-transplant post remission therapy Jacob M. Rowe 9.40 Allogeneic transplant for older patients with AML: GITMO experience Alessandro Rambaldi Therapy of a fit 70 years old individual with AML Richard F. Schlenk APL in 2014: next challenges for the final cure Francesco Lo Coco Conclusions Sergio Amadori Coffee break Plenary Lecture Regulation of self renewal in cancer stem cells Pier Giuseppe Pelicci Presented by: Roberto Lemoli SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL NEOPLASIAS Chairmen: Andrea Bacigalupo, tbd Pathophysiology and clinical features Valerio Del Bono Infections with multidrug-resistant pathogens Gian Maria Rossolini IgM concentrated: rationale for its use in hematology in the era of "bad bugs" Fabio Tumietto

4 12.45 IgM enriched immunoglobulins (Pentaglobin) and defribotide in the prophylaxis of toxicity after allogenic hematopoietic transplantation in acute leukemia Giuseppe Milone Lunch CHRONIC LYMPHOCYTIC LEUKEMIA Chairmen: Giovanni Pizzolo, Enrica Morra Introduction Manlio Ferrarini NoTCH1 mutations: pathogenesis and clinical significance Davide Rossi Transforming response prediction to chemo-immunotherapy using genome technologies Anna Schuh Do the next molecular markers have an impact in treatment strategy? Gianluca Gaidano First line therapy: what are the options today? Marco Montillo Ultra-high risk patients: definition and treatment pathway in the era of novel drug landscape Peter Dreger Break Second line therapy: what are the options today? Leblond Véronique Immunotherapeutic strategies including transplant John G. Gribben A look at the future: new options? George Follows Conclusions Giovanni Pizzolo End of session Friday, May 23 PH-NEGATIVE MYELOPROLIFERATIVE SYNDROMES Chairmen: Tiziano Barbui, Marco Gobbi 8.00 Introduction Tiziano Barbui 8.05 Molecular diagnosis of MPNs in practice Robert Kralovics 8.25 Molecular prognostic profiling in MF Alessandro Vannucchi 8.45 Therapeutic challenges in PV and ET patients conventionally classified at low-risk for thrombosis Tiziano Barbui 9.05 Prefibrotic MF: a diagnosis that counts Giovanni Barosi

5 9.25 Are we ready for treatment recommendations with ruxolitinib in myelofibrosis? Jean-Jacques Kiladjian Deciding hematopoietic stem-cell transplant in myelofibrosis Nicolaus Kröger Conclusions Marco Gobbi Coffee break NEW MOLECULAR INSIGHTS AND THERAPEUTIC STRATEGIES IN ACUTE LYMPHOCYTIC LEUKEMIA Chairmen: Dieter Hoelzer, Felicetto Ferrara Introduction Dieter Hoelzer New markers for the diagnosis of ALL: including NGS? Robin Foà Minimal residual disease: comparison of different methods Monika Brüggemann Current treatment results without antibodies Renato Bassan Antibody therapy Dieter Hoelzer Targeted therapy Oliver G. Ottmann Therapy oft-all: what can we learn from other T-cell neoplasies? Pier Luigi Zinzani Risk factors in adult T-ALL Vahid Asnafi Stem cell transplantation Andrea Bacigalupo Conclusions Roberto Foà Lunch MYELODYSPLASTIC SYNDROMES Chairmen: Giorgina Specchia, tbd Introduction Giorgina Specchia Classification tbd Prognostic models to predict survival Valeria Santini Low-risk patients with deletions in chromosome 5 Esther Oliva Therapeutic strategies tbd

6 16.25 Five years after azacitidine approval: remaining challenges Thomas Prebet Who and when in the course of the disease to transplant classification Maria Teresa Voso Conclusions tbd Saturday, May 24 CHRONIC MYELOID LEUKEMIAS: WHAT IS NEW? Chairmen: John M. Goldman, Angelo M. Carella 8.00 Introduction Angelo M. Carella 8.05 The bases for clinical heterogeneity Giuseppe Saglio 8.25 Initial choice of therapy Michele Baccarani 8.45 Molecular monitoring Andreas Hochhaus 9.05 Alternative approaches in eradicating the malignant clone Richard A. Van Etten 9.25 Early molecular response is predictive of long-term outcome? Susan Branford 9.45 Coffee break Current clinical options after resistance/intolerance to 1G/2G TKIs Fabrizio Pane Safety profiles of different TKIsC Carlo Gambacorti-Passerini IFN: "new ways with old remedies?" Rudiger Hehlmann When should we transplant? Jane Apperley How we will manage CML in the next decade? Stephen O'Brien Conclusions John M. Goldman End of the conference [ Adressed to ] Physicians specialized in Hematology, Oncology and Biologists.

7 [ Scientific Coordinators ] Angelo Michele Carella U.O.C. Ematologia I IRCCS A.O.U. San Martino-IST Genoa (I) Felicetto Ferrara U.O. Ematologia con Trapianto di Midollo Osseo A.O. A. Cardarelli Naples (I) Enrica Morra U.O. Ematologia e Trapianti di Midollo A.O. Ospedale Niguarda Cà Granda Milan (I) [ Speakers and Chairmen ] Daniele Alberti Novartis Farma Origgio, MI (I) Sergio Amadori U.O.C. Ematologia Policlinico Tor Vergata Roma (I) Emanuela Angelucci U.O. Ematologia e Centro Trapianti Midollo Osseo Ospedale "Armando Businco" Azienda USL 8 Cagliari (I) Jane F. Apperley Departmento of Haematology Hammersmith Hospital Imperial College London London (UK) William Arcese Dipartimento di Biopatologia e Diagnostica per Immagini Università di Tor Vergata Roma (I) Vahid Asnafi Department of Hematology Hôpital Necker-Enfants Malades Université Paris-5 Descartes Paris (F) Michele Baccarani Department of Hematology/Oncology L. e A. Seragnoli University of Bologna S. Orsola-Malpighi Hospital Bologna (I) Andrea Bacigalupo Divisione di Ematologia e Trapianto di Midollo Osseo IRCCS A.O.U. San Martino-IST Genova (I)

8 Tiziano Barbui U.O. di Ematologia A.O. Ospedali Riuniti Bergamo(I) Giovanni Barosi I Clinica Medica Fondazione IRCCS Policlinico San Matteo Pavia (I) Renato Bassan Ospedale dell'angelo Azienda ULSS 12 Veneziana Venezia Mestre (I) Alf Bernhardt Hematological Franchise Roche Basel (CH) Alberto Bosi Cattedra di Ematologia Università degli Studi Firenze (I) Susan Branford Department of Genetics and Molecular Pathology Centre for Cancer Biology Adelaide (AUS) Monika Brüggemann Department of Hematology University Hospital Schleswig-Holstein Kiel (D) Alan K. Burnett School of Medicine Cardiff University Cardiff (UK) James Carmichael Celgene Institute Translational Research Europe Seville (S) Adam Craig Development and Medical Officer Sunesis Pharmaceuticals, Inc South San Francisco (USA) Fabio Ciceri Divisione di Ematologia e BMT Istututo Scientifico San Raffaele Milano (I) Valerio Del Bono U.O. Malattie Infettive IRCCS A.O.U. San Martino-IST Genoa (I) Peter Dreger Department of Medicine V University of Heidelberg Heidelberg (D)

9 Andreas Engert Department of Internal Medicine I German Hodgkin Study Group University Hospital Cologne (D) Brunangelo Falini Cattedra di Ematologia Università - Policlinico Monteluce Perugia (I) Massimo Federico Centro Oncologico Modenese A.O. di Modena Modena (I) Manlio Ferrarini Direzione Scientifica IRCCS A.O.U. San Martino-IST Genova (I) George Follows Cambridge University Hospitals NHS Foundation Trust University of Cambridge Cambridge (UK) Robin Foà Dip. di Biotecnologie Cellulari Ematologia Università "La Sapienza" Roma (I) Gianluca Gaidano A.S.O. Maggiore della Carità Università del Piemonte Orientale Amedeo Avogadro Novara (I) Carlo Gambacorti-Passerini A.O. San Gerardo Università degli Studi di Milano Bicocca Monza (I) Marco Gobbi Clinica di Ematologia IRCCS A.O.U. San Martino-IST Genova (I) John M. Goldman Department of Haematology Imperial College London London (UK) John G. Gribben Bart's Cancer Institute Queen Mary University of London London (UK) Rudiger Hehlmann III Medizinische Klinik Ruprecht-Karls-Universität Heidelberg (D)

10 Andreas Hochhaus Klinik für Innere Medizin II Universitätsklinikum Jena Jena (D) Dieter Hoelzer Medizinische Klinik III University Hospital Frankfurt (D) Jean-Jacques Kiladjian Centre d'investigations Cliniques Saint-Louis Hospital and Paris Diderot University Paris (F) Robert Kralovics CeMM Research Center for Molecular Medicine Medical University of Vienna Vienna (A) Nicolaus Kröger Center for Stem Cell Transplantation University Medical Center Hamburg (D) Véronique Leblond Department of Hematology Hôpital Pitié-Salpêtrière APHP Paris (F) Roberto M. Lemoli Clinica di Ematologia Dipartimento di Medicina Interna e Specialità Mediche - DiMI IRCCS A.O.U. San Martino-IST Genova (I) Francesco Lo Coco Dipartimento di Biopatologia e Diagnostica per immagini Università di Tor Vergata Roma (I) Giovanni Martinelli Istituto di Ematologia e Oncologia Medica "L. A. Seragnoli" Università degli Studi - A.O. di Bologna Policlinico S. Orsola-Malpighi Bologna (I) Giuseppe Milone Divisione Clinicizzata di Ematologia Ospedale Ferrarotto Catania (I) Marco Montillo U.O. di Ematologia e Trapianti di Midollo A.O. Niguarda Ca' Granda Milano (I) Stephen O'Brien Northern Institute for Cancer Research Newcastle University Medical School Newcastle (UK)

11 Esther Natalie Oliva Divisione di Ematologia A.O. Bianchi Melacrino Morelli Reggio Calabria (I) Gert J. Ossenkoppele Department of Haematology VU University Medical Centre Amsterdam (NL) Oliver G. Ottmann Department of Hematology and Oncology Goethe University Frankfurt (D) Fabrizio Pane U.O. Ematologica e trapianti di midollo A.O.U. Policlinico Napoli (I) Pier Giuseppe Pelicci Dipartimento di Oncologia Sperimentale Istituto Europeo di Oncologia (IEO) Milano (I) Giovanni Pizzolo Dipartimento Medicina Clinica e Sperimentale Policlinico "G.B. Rossi" Verona (I) Thomas Prebet Hematology Department Institut Paoli-Calmettes and Aix-Marseille Université Marseille (F) Alessandro Rambaldi U.S.C. di Ematologia A. O. Ospedali Riuniti Bergamo (I) Davide Rossi Dipartimento di Medicina Clinica e Sperimentale Università del Piemonte Orientale Amedeo Avogadro Novara (I) Giuseppe Rossi U.O. Ematologia A.O. Spedali Civili Brescia (I) Gian Maria Rossolini Dipartimento Biotecnologie Mediche Università degli Studi Siena (I) Jacob M. Rowe Department of Haematology Shaare Zedek Medical Centre Jerusalem (IL)

12 Giuseppe Saglio U.O. Direz. Universitaria Medicina Interna II A.S.O. San Luigi Orbassano, TO, (I) Valeria Santini Unità Funzionale di Ematologia A.O.U. Careggi Firenze (I) Richard F. Schlenk Department of Internal Medicine III University Hospital of Ulm Ulm (D) Anna Schuh NIHR Biomedical Research Centre University of Oxford Oxford (UK) Giorgina Specchia Cattedra di Ematologia Università degli Studi - Policlinico Bari (I) Fabio Tumietto Istituto di Malattie Infettive A.O. di Bologna - Policlinico S. Orsola-Malpighi Bologna (I) Richard A. Van Etten Molecular Oncology Research Institute Division of Hematology/Oncology Tufts Medical Center Boston (USA) Alessandro M. Vannucchi Unità Funzionale di Ematologia Università degli Studi di Firenze Firenze (I) Maria Teresa Voso Istituto di Ematologia Università Cattolica Sacro Cuore Roma (I) Pier Luigi Zinzani Istituto di Ematologia ed Oncologia Medica Università - A.O. di Bologna Policlinico S. Orsola-Malpighi Bologna (I) [ Venue ] Grand Hotel Miramare Via Milite Ignoto, 30 Santa Margherita Ligure (GE), Italy